Nektar Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Nektar Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 8.7% bzw. 13.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 25.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -283.3% betragen.

Wichtige Informationen

8.7%

Wachstumsrate der Gewinne

25.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	13.1%
Zukünftige Eigenkapitalrendite	-283.3%
Analystenabdeckung	Low
Zuletzt aktualisiert	25 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

Jun 19

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Feb 15

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Dec 31

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Aug 19

Nektar: Time To Abandon Ship

Jul 17

Nektar promotes internal executive to CFO role

Jul 01

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

May 11

After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline

Apr 04

Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts

Mar 09

Nektar Therapeutics: Beaten Down By 2020

Jan 26

We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth

Jan 13

Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Trimmed Their Revenue Forecasts By 11%

Dec 09

Nektar Therapeutics (NASDAQ:NKTR) Is In A Strong Position To Grow Its Business

Oct 05

Nektar Therapeutics' Short Covering Surges By 200% In 2 Weeks

Sep 29

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:NKTR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	67	-184	-75	N/A	5
12/31/2025	66	-175	-178	-145	5
12/31/2024	74	-156	-155	-148	5
3/31/2024	90	-176	-189	-189	N/A
12/31/2023	90	-276	-193	-193	N/A
9/30/2023	88	-294	-204	-203	N/A
6/30/2023	88	-307	-245	-244	N/A
3/31/2023	89	-415	-269	-267	N/A
12/31/2022	92	-368	-310	-304	N/A
9/30/2022	95	-454	-409	-398	N/A
6/30/2022	96	-525	-430	-416	N/A
3/31/2022	103	-491	-440	-424	N/A
12/31/2021	102	-524	-428	-413	N/A
9/30/2021	100	-495	-371	-360	N/A
6/30/2021	105	-474	-321	-311	N/A
3/31/2021	126	-429	-322	-312	N/A
12/31/2020	153	-444	-321	-313	N/A
9/30/2020	163	-439	-349	-340	N/A
6/30/2020	163	-429	-368	-356	N/A
3/31/2020	137	-460	-347	-326	N/A
12/31/2019	115	-441	-355	-329	N/A
9/30/2019	121	-427	-352	-321	N/A
6/30/2019	119	-424	-352	-324	N/A
3/31/2019	1,184	657	671	690	N/A
12/31/2018	1,193	681	704	718	N/A
9/30/2018	1,249	746	747	755	N/A
6/30/2018	1,374	903	913	920	N/A
3/31/2018	321	-129	-105	-98	N/A
12/31/2017	308	-97	N/A	-80	N/A
9/30/2017	250	-105	N/A	-52	N/A
6/30/2017	133	-209	N/A	-173	N/A
3/31/2017	131	-198	N/A	-128	N/A
12/31/2016	165	-154	N/A	-117	N/A
9/30/2016	167	-165	N/A	-140	N/A
6/30/2016	191	-130	N/A	-126	N/A
3/31/2016	181	-134	N/A	-160	N/A
12/31/2015	231	-81	N/A	-73	N/A
9/30/2015	211	-73	N/A	-23	N/A
6/30/2015	284	6	N/A	-55	N/A
3/31/2015	290	26	N/A	-16	N/A
12/31/2014	201	-54	N/A	-142	N/A
9/30/2014	212	-56	N/A	-64	N/A
6/30/2014	140	-143	N/A	-37	N/A
3/31/2014	146	-153	N/A	-63	N/A
12/31/2013	149	-162	N/A	-39	N/A
9/30/2013	139	-167	N/A	-140	N/A
6/30/2013	96	-194	N/A	-147	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NKTR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: NKTR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: NKTR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: NKTRDie Einnahmen des Unternehmens (13.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: NKTRDie Einnahmen des Unternehmens (13.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: NKTR wird voraussichtlich in 3 Jahren unrentabel sein.

Nektar Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 12%

Price target decreased by 83% to US$0.50

Price target increased by 21% to US$2.88

Price target increased by 14% to US$2.70

Price target decreased by 7.3% to US$2.35

Price target increased by 18% to US$3.00

Recent updates

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Nektar Therapeutics to Report Q1, 2024 Results on May 09, 2024

Nektar Therapeutics, Annual General Meeting, Jun 05, 2024

New major risk - Share price stability

Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC

Consensus EPS estimates fall by 12%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC

Nektar Therapeutics to Report Q4, 2023 Results on Mar 04, 2024

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Price target decreased by 83% to US$0.50

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement

Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nektar Therapeutics to Report Q3, 2023 Results on Nov 07, 2023

Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer

Price target increased by 21% to US$2.88

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis

Price target increased by 14% to US$2.70

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Nektar Therapeutics Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

Nektar Therapeutics to Report Q2, 2023 Results on Aug 08, 2023

Price target decreased by 7.3% to US$2.35

New minor risk - Market cap size

Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 2000 Index

New minor risk - Market cap size

Nektar Therapeutics Receives Notice from The Nasdaq Global Select Market Due to Non-Compliance with the Minimum Bid Price Rule

Price target increased by 18% to US$3.00

Consensus EPS estimates fall by 63%, revenue upgraded

Price target decreased by 7.8% to US$2.70

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Nektar Therapeutics Reports Impairment of Goodwill for the First Quarter Ended March 31, 2023

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 21% to US$3.60

CEO, President & Director recently sold US$59k worth of stock

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Insufficient new directors

CEO, President & Director recently sold US$136k worth of stock

Insider recently sold US$48k worth of stock

Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15, Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Nektar Therapeutics to Report Q3, 2022 Results on Nov 03, 2022

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

Independent Director notifies of intention to sell stock

Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (Eadv) Congress

Insider notifies of intention to sell stock

CEO, President & Director recently sold US$65k worth of stock

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Nektar Therapeutics Announces Preclinical Publication of Data for NKTR-255 and Its Observed Improvement of NK Cell Function in Multiple Myeloma

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nektar Therapeutics Provides Earnings Guidance for the Year 2022

Nektar Therapeutics to Report Q2, 2022 Results on Aug 04, 2022

Nektar: Time To Abandon Ship

Nektar Promotes Jillian B. Thomsen to Senior Vice President

Nektar promotes internal executive to CFO role

Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 1000 Dynamic Index

Price target decreased to US$4.83

Nektar Therapeutics Reviews Interim Efficacy and Safety Data from the Ongoing Phase 2 Double Blinded, Placebo-Controlled Study

CEO, President & Director recently sold US$144k worth of stock

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target decreased to US$5.96